bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure 1 from Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients
Authors: LaCerte Carl , Ivaturi Vijay , Gobburu Joga , Greer Jacqueline M. , Doyle L. Austin , Wright John J. , Karp Judith E. , Rudek Michelle A.
Published: April 2023

Observed Total Flavopiridol Concentrations versus Time for Bolus and Hybrid Administration.
Supplementary Figure 1 from Prognostic Utility of a New mRNA Expression Signature of Gleason Score
Authors: Sinnott Jennifer A. , Peisch Sam F. , Tyekucheva Svitlana , Gerke Travis , Lis Rosina , Rider Jennifer R. , Fiorentino Michelangelo , Stampfer Meir J. , Mucci Lorelei A. , Loda Massimo , Penney Kathryn L.
Published: April 2023

Supplementary Figure 1. Comparisons of the predicted probability of high Gleason score based on the original 157-gene signature calculated on the 75 men in the PHS in the overlap between the Illumina and Affymetrix studies. The x-axis takes values of the signature calculated using the Illumina gene expression data, and the y-axis takes values of the signature calculated using the Affymetrix gene expression data.
Supplementary Figure S4 from Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma
Authors: Sagawa Morihiko , Ohguchi Hiroto , Harada Takeshi , Samur Mehmet K. , Tai Yu-Tzu , Munshi Nikhil C. , Kizaki Masahiro , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

YAP1 did not alter upon RRM1-knockdown.
Figure S2 from A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Authors: Singh Anurag K. , Winslow Timothy B. , Kermany Mohammad Habiby , Goritz Vincent , Heit Lilia , Miller Austin , Hoffend Nicholas C. , Stein Leighton C. , Kumaraswamy Lalith K. , Warren Graham W. , Bshara Wiam , Odunsi Kunle , Matsuzaki Junko , Abrams Scott I. , Schwaab Thomas , Muhitch Jason B.
Published: April 2023

Supplementary figure S2 shows immunomodulation of tumor cells following high-dose radiation.
Figure S1 from A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Authors: Singh Anurag K. , Winslow Timothy B. , Kermany Mohammad Habiby , Goritz Vincent , Heit Lilia , Miller Austin , Hoffend Nicholas C. , Stein Leighton C. , Kumaraswamy Lalith K. , Warren Graham W. , Bshara Wiam , Odunsi Kunle , Matsuzaki Junko , Abrams Scott I. , Schwaab Thomas , Muhitch Jason B.
Published: April 2023

Supplementary figure S1 shows radiation induces changes in surface expression of immunogenic molecules.
Multivariate Cox regression analysis of the overall survival according to RMH prognostic score and HPD adapted RECIST classes (landmark analysis). from Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Authors: Champiat Stéphane , Dercle Laurent , Ammari Samy , Massard Christophe , Hollebecque Antoine , Postel-Vinay Sophie , Chaput Nathalie , Eggermont Alexander , Marabelle Aurélien , Soria Jean-Charles , Ferté Charles
Published: April 2023

Practically, patients with SD, PD and HPD lead 4.9, 16.5 and 25.9 fold increase in the death the death hazard compared to patients with CR-PR, respectively. *HPD adapted RECIST classes: complete response (CR), partial response (PR) and stable disease (SD) remained as defined by RECIST 1.1. Regarding progressive disease patients, these were allocated to PD non-HPD and to HPD. HPD patients are defined as progressive disease (PD) by RECIST 1.1 at the first evaluation and an increase {greater than or equal to} two-fold in the TGR EXPERIMENTAL compared to REFERENCE period.
Supplementary Figures 1-2 from ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET–Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence
Authors: Wang Jieyi , Anderson Mark G. , Oleksijew Anatol , Vaidya Kedar S. , Boghaert Erwin R. , Tucker Lora , Zhang Qian , Han Edward K. , Palma Joann P. , Naumovski Louie , Reilly Edward B.
Published: April 2023

ABBV-399, a c-Met Antibody Drug Conjugate that Targets Both MET Amplified and c-Met Overexpressing Tumors, Irrespective of MET Pathway Dependence. Figure S1 shows ABBV-399 is internalized upon binding to tumor cells. Figure S2 shows the down-regulation of phospho- and total c-Met and downstream signaling molecules upon treatment with ABBV-399
Table S1 from Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment
Authors: Niu Xiaomin , Liu Fatao , Zhou Yi , Zhou Zhen , Zhou Daizhan , Wang Ting , Li Ziming , Ye Xiangyun , Yu Yongfeng , Weng Xiaoling , Zhang Hong , Ye Junyi , Liao Meilin , Liu Yun , Chen Zhiwei , Lu Shun
Published: April 2023

Data summary of methyl-sensitive cut counting sequencing (MSCC) sequencing of the 4 samples (8 libraries).
Supplementary Table S4 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

Clinicopathological factors in 4 cases with PD-L1 focal amplification
Supplementary Fig S2 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

Copy number alterations in SCLC tumor samples based on SNP 6.0 Array data.
Suppl. Figure 4 from Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy
Authors: Zeng Qinghai , Liu Jianye , Cao Peiguo , Li Jingjing , Liu Xiaoming , Fan Xiaojun , Liu Ling , Cheng Yan , Xiong Wei , Li Jigang , Bo Hao , Zhu Yuxing , Yang Fei , Hu Jun , Zhou Ming , Zhou Yanhong , Zou Qiong , Zhou Jianda , Cao Ke
Published: April 2023

Involvement of REDD1 and miR-22 in Taxol chemosensitivity in EJ and BIU87 cells. (A-B) The effect of knockdown or overexpression of REDD1 or miR-22 on cell proliferation and apoptosis was examined in EJ and BIU87 BUC cells. CCK-8 was used to detect cell proliferation ability, and propidium iodide and annexin V staining were used to detect apoptosis. (C-D) Protein expression of c-caspase 3, c-PARP, LC3-I/II, and REDD1 were analyzed by western blot following modulation of REDD1 or miR-22 and/or treatment with Taxol in EJ and BIU87 cells. ***P<0.001, **P<0.01, *P<0.05.
Supplementary Figure S1 from Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis
Authors: Lin Chenyu , Zhang Shengnan , Wang Ying , Wang Yuanshu , Nice Edouard , Guo Changying , Zhang Erhao , Yu Liting , Li Mengwei , Liu Chen , Hu Lirong , Hao Jingchao , Qi Weiyan , Xu Hanmei
Published: April 2023

Relative qRT-PCR expression levels of lncRNAs for 15 pairs of ESCC and adjacent normal tissues.
Supplemental Figure 1B from Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies
Authors: Mehrotra Shailly , Gopalakrishnan Mathangi , Gobburu Jogarao , Ji Jiuping , Greer Jacqueline M. , Piekarz Richard , Karp Judith E. , Pratz Keith W. , Rudek Michelle A.
Published: April 2023

Relationship between AUC and Cmax at steady state (B
Supplementary Tables from Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
Authors: Suzawa Ken , Offin Michael , Lu Daniel , Kurzatkowski Christopher , Vojnic Morana , Smith Roger S. , Sabari Joshua K. , Tai Huichun , Mattar Marissa , Khodos Inna , de Stanchina Elisa , Rudin Charles M. , Kris Mark G. , Arcila Maria E. , Lockwood William W. , Drilon Alexander , Ladanyi Marc , Somwar Romel
Published: April 2023

Supplementary Tables 1A and 1B
Figure S6 from Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
Authors: Suzawa Ken , Offin Michael , Lu Daniel , Kurzatkowski Christopher , Vojnic Morana , Smith Roger S. , Sabari Joshua K. , Tai Huichun , Mattar Marissa , Khodos Inna , de Stanchina Elisa , Rudin Charles M. , Kris Mark G. , Arcila Maria E. , Lockwood William W. , Drilon Alexander , Ladanyi Marc , Somwar Romel
Published: April 2023

Tumor volume changes and body weight changes in vivo in treated LUAD12C xenografts.
Figure S5 from Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
Authors: Suzawa Ken , Offin Michael , Lu Daniel , Kurzatkowski Christopher , Vojnic Morana , Smith Roger S. , Sabari Joshua K. , Tai Huichun , Mattar Marissa , Khodos Inna , de Stanchina Elisa , Rudin Charles M. , Kris Mark G. , Arcila Maria E. , Lockwood William W. , Drilon Alexander , Ladanyi Marc , Somwar Romel
Published: April 2023

Mutant KRAS stabilizes MET protein.
Figure S4 from Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
Authors: Suzawa Ken , Offin Michael , Lu Daniel , Kurzatkowski Christopher , Vojnic Morana , Smith Roger S. , Sabari Joshua K. , Tai Huichun , Mattar Marissa , Khodos Inna , de Stanchina Elisa , Rudin Charles M. , Kris Mark G. , Arcila Maria E. , Lockwood William W. , Drilon Alexander , Ladanyi Marc , Somwar Romel
Published: April 2023

Trametinib suppresses MYC expression.
Figure S1. Pathway-guided vaccine response predictions. from PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer
Authors: Qian David C. , Xiao Xiangjun , Byun Jinyoung , Suriawinata Arief A. , Her Stephanie C. , Amos Christopher I. , Barth Richard J.
Published: April 2023

Response prediction scores for 22 rounds of leave-one-out cross-validation are presented. The test set individual in each round is denoted by a black asterisk, while training set responders and non-responders are denoted by blue dots and red dots, respectively. Test set individuals with scores above/below the dashed line were predicted to be vaccine responders/non-responders. Of the variants found to be associated with vaccine response among training set individuals (P < 0.005), up-weighting in the prediction model was applied to those within genes that participate in the following pathways: (A) no pathway, (B) KEGG: Extracellular matrix receptor interactions, (C) KEGG: Natural killer cell mediated cytotoxicity, (D) PID: ÃŽÂ±VÃŽÂ²3 integrin pathway, (E) PID: Caspase pathway, (F) PID: SHP2 pathway, (G) REACTOME: Cell surface interactions at the vascular wall, (H) REACTOME: PPARÃŽÂ± activates gene expression, (I) PID: ÃŽÂ±MÃŽÂ²2 integrin pathway, (J) PID: Integrin 1 pathway, and (K) REACTOME: Metabolism of amino acids and derivatives.
Figure S2 from Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
Authors: Suzawa Ken , Offin Michael , Lu Daniel , Kurzatkowski Christopher , Vojnic Morana , Smith Roger S. , Sabari Joshua K. , Tai Huichun , Mattar Marissa , Khodos Inna , de Stanchina Elisa , Rudin Charles M. , Kris Mark G. , Arcila Maria E. , Lockwood William W. , Drilon Alexander , Ladanyi Marc , Somwar Romel
Published: April 2023

Overexpression of KRAS mutant mediates resistance to MET directed therapies
Table S3 from Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma
Authors: Hausner Sven H. , Bold Richard J. , Cheuy Lina Y. , Chew Helen K. , Daly Megan E. , Davis Ryan A. , Foster Cameron C. , Kim Edward J. , Sutcliffe Julie L.
Published: April 2023

Shows the maximum standard uptake values (SUVmax) at the 1 and 3 hour time points for the five subjects, decay corrected to the time of injection.
Figure S2 from The Highly Metastatic Nature of Uterine Cervical/Endometrial Cancer Displaying Tumor-Related Leukocytosis: Clinical and Preclinical Investigations
Authors: Sasano Tomoyuki , Mabuchi Seiji , Kozasa Katsumi , Kuroda Hiromasa , Kawano Mahiru , Takahashi Ryoko , Komura Naoko , Yokoi Eriko , Matsumoto Yuri , Hashimoto Kae , Sawada Kenjiro , Morii Eiichi , Kimura Tadashi
Published: April 2023

Invasive ability of the ME180-GCSF or ME180-control cells in vitro.
Supplementary Methods from Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma
Authors: Hausner Sven H. , Bold Richard J. , Cheuy Lina Y. , Chew Helen K. , Daly Megan E. , Davis Ryan A. , Foster Cameron C. , Kim Edward J. , Sutcliffe Julie L.
Published: April 2023

Describes additional methods
Figure S1 from Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma
Authors: Hausner Sven H. , Bold Richard J. , Cheuy Lina Y. , Chew Helen K. , Daly Megan E. , Davis Ryan A. , Foster Cameron C. , Kim Edward J. , Sutcliffe Julie L.
Published: April 2023

Shows a representative time-activity curves of [18F]αvβ6-BP for whole blood and plasma. Data are expressed as decay-corrected percent of injected dose per gram of sample [dc %ID/g].
Table S1 from Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3
Authors: Weberpals Johanne I. , Lo Bryan , Duciaume Marc M. , Spaans Johanna N. , Clancy Aisling A. , Dimitroulakos Jim , Goss Glenwood D. , Sekhon Harman S.
Published: April 2023

50 Genes Targeted by the Ion AmpliSeq Cancer Hotspot Panel
Figure S6 from Vulvar Squamous Cell Carcinoma (VSCC) as Two Diseases: HPV Status Identifies Distinct Mutational Profiles Including Oncogenic Fibroblast Growth Factor Receptor 3
Authors: Weberpals Johanne I. , Lo Bryan , Duciaume Marc M. , Spaans Johanna N. , Clancy Aisling A. , Dimitroulakos Jim , Goss Glenwood D. , Sekhon Harman S.
Published: April 2023

Prognosis of patients (n=43) stratified by the number of observed mutations
Supplemental video S1 from Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner
Authors: Kreutzman Anna , Colom-Fernández Beatriz , Jiménez Ana Marcos , Ilander Mette , Cuesta-Mateos Carlos , Pérez-García Yaiza , Arévalo Cristina Delgado , Brück Oscar , Hakanen Henna , Saarela Jani , Ortega-Carrión Alvaro , de Rosendo Ana , Juanes-García Alba , Steegmann Juan Luis , Mustjoki Satu , Vicente-Manzanares Miguel , Muñoz-Calleja Cecilia
Published: April 2023

100nM dasatinib was added on a monolayer of HUVECs.
Supplementary Materials and Methods from Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/β-catenin/CBP signaling
Authors: Wu Geyan , Cao Lixue , Zhu Jinrong , Tan Zhanyao , Tang Miaoling , Li Ziwen , Hu Yameng , Yu Ruyuan , Zhang Shuxia , Song Libing , Li Jun
Published: April 2023

Supplementary information to support primary data.
Supplementary table 7 from Transcription Factor Myeloid Zinc-Finger 1 Suppresses Human Gastric Carcinogenesis by Interacting with Metallothionein 2A
Authors: Lin Shuye , Wang Xiaoyue , Pan Yuanming , Tian Rongmeng , Lin Bonan , Jiang Guosheng , Chen Keqiang , He Yuqi , Zhang Lulu , Zhai Wanli , Jin Peng , Yang Lang , Li Guoqiang , Wu Yun , Hu Jiang , Gong Wanghua , Chang Zhijie , Sheng Jian-qiu , Lu Youyong , Wang Ji Ming , Huang Jiaqiang
Published: April 2023

Supplementary table
Supplementary Figures from Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer
Authors: Zuo Wen-Jia , Jiang Yi-Zhou , Wang Yu-Jie , Xu Xiao-En , Hu Xin , Liu Guang-Yu , Wu Jiong , Di Gen-Hong , Yu Ke-Da , Shao Zhi-Ming
Published: April 2023

Supplementary Figure S1. Flowchart of study design. Supplementary Figure S2. Protein structure visualizations of the HER2 somatic mutations. Supplementary Figure S3. HER2 mutations L768S and V773L induce HER2 internalization. Supplementary Figure S4. Kaplan-Meier estimates of relapse-free survival (RFS) according to HER2 mutation in different regions.
Supplemental Figure 2 from CD103 and Intratumoral Immune Response in Breast Cancer
Authors: Wang Zhi-Qiang , Milne Katy , Derocher Heather , Webb John R. , Nelson Brad H. , Watson Peter H.
Published: April 2023

Supplemental Figure 2: Prognostic impact of CD103 and CD8 alone and combination in the Basel-like subset of breast cancers.
Supplementary Table from ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types
Authors: Chüeh Anderly C. , Tse Janson W.T. , Dickinson Michael , Ioannidis Paul , Jenkins Laura , Togel Lars , Tan BeeShin , Luk Ian , Davalos-Salas Mercedes , Nightingale Rebecca , Thompson Matthew R. , Williams Bryan R.G. , Lessene Guillaume , Lee Erinna F. , Fairlie Walter D. , Dhillon Amardeep S. , Mariadason John M.
Published: April 2023

Supplementary Table
Supplementary Table S4 from Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation
Authors: Tanaka Noriaki , Patel Ameeta A. , Tang Lin , Silver Natalie L. , Lindemann Antje , Takahashi Hideaki , Jaksik Roman , Rao Xiayu , Kalu Nene N. , Chen Tseng-Cheng , Wang Jiping , Frederick Mitchell J. , Johnson Faye , Gleber-Netto Frederico O. , Fu Siqing , Kimmel Marek , Wang Jing , Hittelman Walter N. , Pickering Curtis R. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

GO enrichment analysis identified two significant pathways involving G1/S phase transition and cell cycle checkpoint as annotated in the RPPA heatmap.
Table S3 from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
Authors: Audenet François , Isharwal Sumit , Cha Eugene K. , Donoghue Mark T.A. , Drill Esther N. , Ostrovnaya Irina , Pietzak Eugene J. , Sfakianos John P. , Bagrodia Aditya , Murugan Paari , Dalbagni Guido , Donahue Timothy F. , Rosenberg Jonathan E. , Bajorin Dean F. , Arcila Maria E. , Hechtman Jaclyn F. , Berger Michael F. , Taylor Barry S. , Al-Ahmadie Hikmat , Iyer Gopa , Bochner Bernard H. , Coleman Jonathan A. , Solit David B.
Published: April 2023

Comparison of the sensitivity and specificity of different screening strategies to identify patients with UTUC related to a Lynch syndrome.
Table S1 from Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma
Authors: Audenet François , Isharwal Sumit , Cha Eugene K. , Donoghue Mark T.A. , Drill Esther N. , Ostrovnaya Irina , Pietzak Eugene J. , Sfakianos John P. , Bagrodia Aditya , Murugan Paari , Dalbagni Guido , Donahue Timothy F. , Rosenberg Jonathan E. , Bajorin Dean F. , Arcila Maria E. , Hechtman Jaclyn F. , Berger Michael F. , Taylor Barry S. , Al-Ahmadie Hikmat , Iyer Gopa , Bochner Bernard H. , Coleman Jonathan A. , Solit David B.
Published: April 2023

Cancer associated genes panel of MSK-IMPACT assay.
Supplementary Table S2 from Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer
Authors: Tokunaga Ryuma , Xiu Joanne , Johnston Curtis , Goldberg Richard M. , Philip Philip A. , Seeber Andreas , Naseem Madiha , Lo Jae Ho , Arai Hiroyuki , Battaglin Francesca , Puccini Alberto , Berger Martin D. , Soni Shivani , Zhang Wu , Hwang Jimmy J. , Shields Anthony F. , Marshall John L. , Baba Hideo , Korn W. Michael , Lenz Heinz-Josef
Published: April 2023

Supplementary Table S2. Patients characteristics.
Supplementary Data from Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Authors: Siravegna Giulia , Sartore-Bianchi Andrea , Nagy Rebecca J. , Raghav Kanwal , Odegaard Justin I. , Lanman Richard B. , Trusolino Livio , Marsoni Silvia , Siena Salvatore , Bardelli Alberto
Published: April 2023

Figure legends for the supp figures
Supplementary Table S1: IMWG Criteria for MRD negativity from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
Authors: Anderson Kenneth C. , Auclair Daniel , Kelloff Gary J. , Sigman Caroline C. , Avet-Loiseau Hervé , Farrell Ann T. , Gormley Nicole J. , Kumar Shaji K. , Landgren Ola , Munshi Nikhil C. , Cavo Michele , Davies Faith E. , Di Bacco Alessandra , Dickey Jennifer S. , Gutman Steven I. , Higley Howard R. , Hussein Mohamad A. , Jessup J. Milburn , Kirsch Ilan R. , Little Richard F. , Loberg Robert D. , Lohr Jens G. , Mukundan Lata , Omel James L. , Pugh Trevor J. , Reaman Gregory H. , Robbins Michael D. , Sasser A. Kate , Valente Nancy , Zamagni Elena
Published: April 2023

Adapted from: Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17:e328-46.
Supplementary Table 6 from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
Authors: Pinto Emilia Modolo , Rodriguez-Galindo Carlos , Choi John Kim , Pounds Stanley , Liu Zhifa , Neale Geoffrey , Finkelstein David , Hicks John M. , Pappo Alberto S. , Figueiredo Bonald C. , Ribeiro Raul C. , Zambetti Gerard P.
Published: April 2023

HLA-DPA1 immunostaining pattern for pediatric normal adrenal cortex, ACTs and infiltrating cells
Supplementary Table 1 from Prognostic Significance of Major Histocompatibility Complex Class II Expression in Pediatric Adrenocortical Tumors: A St. Jude and Children's Oncology Group Study
Authors: Pinto Emilia Modolo , Rodriguez-Galindo Carlos , Choi John Kim , Pounds Stanley , Liu Zhifa , Neale Geoffrey , Finkelstein David , Hicks John M. , Pappo Alberto S. , Figueiredo Bonald C. , Ribeiro Raul C. , Zambetti Gerard P.
Published: April 2023

Clinical Data for Pediatric Adrenocortical Tumor patients
Supplementary Tables 1-4 from Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display
Authors: Altmann Annette , Sauter Max , Roesch Saskia , Mier Walter , Warta Rolf , Debus Jürgen , Dyckhoff Gerhard , Herold-Mende Christel , Haberkorn Uwe
Published: April 2023

S1: Peptide sequences of 16 phage-derived clones; S2: Tumor-to-Tissue Ratio of 177Lu-DOTA-SFITGv6 in HNO97 xenografts; S3: Maximum Standard Uptake values (SUVmax) for PET/CT with 18F-FDG and the 68Ga-DOTA-SFITGv6 for one HNSCC patient; S4: Maximum Standard Uptake values (SUVmax) for PET/CT with 18F-FDG and the 68Ga-DOTA-SFITGv6 for one NSCLC patient
Supplementary File 2 from A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Authors: Paik Paul K. , Shen Ronglai , Berger Michael F. , Ferry David , Soria Jean-Charles , Mathewson Alastair , Rooney Claire , Smith Neil R. , Cullberg Marie , Kilgour Elaine , Landers Donal , Frewer Paul , Brooks Nigel , André Fabrice
Published: April 2023

nanoString codeset list
An integrated supplementary document for 3 figures from Role of Platelet-Derived Tgfβ1 in the Progression of Ovarian Cancer
Authors: Hu Qianghua , Hisamatsu Takeshi , Haemmerle Monika , Cho Min Soon , Pradeep Sunila , Rupaimoole Rajesha , Rodriguez-Aguayo Cristian , Lopez-Berestein Gabriel , Wong Stephen T.C. , Sood Anil K. , Afshar-Kharghan Vahid
Published: April 2023

Figure S1: Effect of platelet Tgfï�¢1 and ovarian cancer cell Tgfï�¢R1 on the number of tumor nodules in orthotopic murine models of ovarian cancer. Figure S2: Quantification of Tgfï�¢R1 mRNA level by qRT-PCR in IG10 and ID8 murine ovarian cancer cells incubated with scrambled siRNA or human specific hTgfï�¢R1 siRNA in vitro for 48 hours (n=6). Figure S3: Effect of platelet Tgfï�¢1 on proliferation of human ovarian cancer cells in vitro. Platelets isolated from whole blood of mice were coincubated with human ovarian cancer cells (SKOV3ip1, OVCAR432, and CaOV3) and cell proliferation rate was measured by quantifying BrdU incorporations
Supplemental Materials and Methods from The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma
Authors: Lowery Caitlin D. , VanWye Alle B. , Dowless Michele , Blosser Wayne , Falcon Beverly L. , Stewart Julie , Stephens Jennifer , Beckmann Richard P. , Bence Lin Aimee , Stancato Louis F.
Published: April 2023

Supplemental methodology, specifically the in vitro cord formation assay and the enzyme-linked immunosorbent assay.
Supplementary information from Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness
Authors: Park So-Yeon , Kim Ji-Young , Choi Jang-Hyun , Kim Jee-Heun , Lee Choong-Jae , Singh Pomila , Sarkar Shubhashish , Baek Jeong-Heum , Nam Jeong-Seok
Published: April 2023

Supplementary information file includes the Supplementary Table Legends, the Supplementary Figure Legends, and Supplementary Materials and Methods.
Supplementary Information from Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma
Authors: Heske Christine M. , Davis Mindy I. , Baumgart Joshua T. , Wilson Kelli , Gormally Michael V. , Chen Lu , Zhang Xiaohu , Ceribelli Michele , Duveau Damien Y. , Guha Rajarshi , Ferrer Marc , Arnaldez Fernanda I. , Ji Jiuping , Tran Huong-Lan , Zhang Yiping , Mendoza Arnulfo , Helman Lee J. , Thomas Craig J.
Published: April 2023

Supplementary Methods and Supplementary Figures
Supplementary Figure S7 from PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma
Authors: Melaiu Ombretta , Mina Marco , Chierici Marco , Boldrini Renata , Jurman Giuseppe , Romania Paolo , D'Alicandro Valerio , Benedetti Maria C. , Castellano Aurora , Liu Tao , Furlanello Cesare , Locatelli Franco , Fruci Doriana
Published: April 2023

This figure includes representative flow cytometry histograms of PD-L1 surface expression in the indicated neuroblastoma cell lines (A and B) and apoptosis of JQ1-treated neuroblastoma cell lines as detected by Annexin V-APC and PI staining (C).
Supplementary legend from Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells
Authors: Das Deepika Sharma , Das Abhishek , Ray Arghya , Song Yan , Samur Mehmet Kemal , Munshi Nikhil C. , Chauhan Dharminder , Anderson Kenneth C.
Published: April 2023

Supplementary legend
Supplementary Figure S5 from PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma
Authors: Melaiu Ombretta , Mina Marco , Chierici Marco , Boldrini Renata , Jurman Giuseppe , Romania Paolo , D'Alicandro Valerio , Benedetti Maria C. , Castellano Aurora , Liu Tao , Furlanello Cesare , Locatelli Franco , Fruci Doriana
Published: April 2023

This figure includes Kaplan-Meier curves of OS according to the MYCN amplification status (A and B), INSS stage (C and D), or age at diagnosis (E and F) with PD-L1+ tumor-cell density (A, C and E) or HLA-I+ tumor-cell density (B, D and F).
Supplemental Figure 4 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Authors: Guenther Lillian M. , Dharia Neekesh V. , Ross Linda , Conway Amy , Robichaud Amanda L. , Catlett Jerrel L. , Wechsler Caroline S. , Frank Elizabeth S. , Goodale Amy , Church Alanna J. , Tseng Yuen-Yi , Guha Rajarshi , McKnight Crystal G. , Janeway Katherine A. , Boehm Jesse S. , Mora Jaume , Davis Mindy I. , Alexe Gabriela , Piccioni Federica , Stegmaier Kimberly
Published: April 2023

Related to Figure 6
Movie S2 from Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma
Authors: Davare Monika A. , Henderson Jacob J. , Agarwal Anupriya , Wagner Jacob P. , Iyer Sudarshan R. , Shah Nameeta , Woltjer Randy , Somwar Romel , Gilheeney Stephen W. , DeCarvalo Ana , Mikkelson Tom , Van Meir Erwin G. , Ladanyi Marc , Druker Brian J.
Published: April 2023

U118MG spheroid treated with 10nM lorlatinib for 72 hrs
Supplemental Figure 1 from A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
Authors: Guenther Lillian M. , Dharia Neekesh V. , Ross Linda , Conway Amy , Robichaud Amanda L. , Catlett Jerrel L. , Wechsler Caroline S. , Frank Elizabeth S. , Goodale Amy , Church Alanna J. , Tseng Yuen-Yi , Guha Rajarshi , McKnight Crystal G. , Janeway Katherine A. , Boehm Jesse S. , Mora Jaume , Davis Mindy I. , Alexe Gabriela , Piccioni Federica , Stegmaier Kimberly
Published: April 2023

Related to Figures 1 & 2
Supplementary Materials and Methods from Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival
Authors: Zhai Lijie , Ladomersky Erik , Lauing Kristen L. , Wu Meijing , Genet Matthew , Gritsina Galina , Győrffy Balázs , Brastianos Priscilla K. , Binder David C. , Sosman Jeffrey A. , Giles Francis J. , James Charles D. , Horbinski Craig , Stupp Roger , Wainwright Derek A.
Published: April 2023

Description of Materials and Methods used to generate the novel IDO1-overexpressing U87 cell line, Western blotting, RT-PCR, cancer genome atlas analysis, as well as high performance liquid chromatography.
Supplementary text from Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer
Authors: Urabe Fumihiko , Matsuzaki Juntaro , Yamamoto Yusuke , Kimura Takahiro , Hara Tomohiko , Ichikawa Makiko , Takizawa Satoko , Aoki Yoshiaki , Niida Shumpei , Sakamoto Hiromi , Kato Ken , Egawa Shin , Fujimoto Hiroyuki , Ochiya Takahiro
Published: April 2023

Supplementary text
Figure S9 from PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
Authors: Sambandam Vaishnavi , Frederick Mitchell J. , Shen Li , Tong Pan , Rao Xiayu , Peng Shaohua , Singh Ratnakar , Mazumdar Tuhina , Huang Chenfei , Li Qiuli , Pickering Curtis R. , Myers Jeffery N. , Wang Jing , Johnson Faye M.
Published: April 2023

Figure S9. PDK1 inhibition and AKT inhibition act synergistically against NOTCH1MUT head and neck squamous cell carcinoma (HNSCC). A. Two NOTCH1WT lines and four NOTCH1MUT lines were treated with 100 nM BAY806946 or 1 µM PQR309 for 24 hours and then subjected to Western blot analysis with the indicated antibodies. B. Parental and PDK1-overexpressing NOTCH1MUT cells were treated with 50 nM GSK212 for 24 hours and then subjected to Western blot analysis with the indicated antibodies. C. Three NOTCH1MUT HNSCC lines were treated with increasing concentrations (0-10 µM, 2-fold dilution) of MK2206 and/or GSK2334470 for 72 hours, and cell viability was assessed using the CellTiter-Glo assay. D. The combination index (CI) for the fractions affected (Fa) for each combination was calculated with the Chou Talalay method using Calcusyn (Biosoft, Cambridge, UK).
Figure S4 from PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition
Authors: Sambandam Vaishnavi , Frederick Mitchell J. , Shen Li , Tong Pan , Rao Xiayu , Peng Shaohua , Singh Ratnakar , Mazumdar Tuhina , Huang Chenfei , Li Qiuli , Pickering Curtis R. , Myers Jeffery N. , Wang Jing , Johnson Faye M.
Published: April 2023

Figure S4. Association between sensitivity to PI3K/mTOR pathway inhibitors and human papilloma virus (HPV) status and proteomic scores in head and neck squamous cell carcinoma (HNSCC) cell lines. A and B. The sensitivity of HPV-positive cells to each drug using area under curve (AUC) values (A) or 70% inhibitory concentration (IC70) values (B) was compared with that of HPV-negative cells; no significant differences were found. P values were calculated using a two-sample t-test. C-D. Spearman correlation analysis was used to assess associations between IC70 values and epithelial to mesenchymal (EMT) and DNA repair proteomic scores with the indicated p values. The dashed blue lines indicate trend line, the red lines indicate local regression line (LOWESS line) and the shaded area represent 95% confidence interval.
Table S5, Table S6, and Table S7 from Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials
Authors: Edwards Jarem , Tasker Annie , Pires da Silva Inês , Quek Camelia , Batten Marcel , Ferguson Angela , Allen Ruth , Allanson Benjamin , Saw Robyn P.M. , Thompson John F. , Menzies Alexander M. , Palendira Umaimainthan , Wilmott James S. , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Antibodies used in CYTOF experiment
Table S2 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Authors: Lambros Maryou B. , Seed George , Sumanasuriya Semini , Gil Veronica , Crespo Mateus , Fontes Mariane , Chandler Rob , Mehra Niven , Fowler Gemma , Ebbs Berni , Flohr Penny , Miranda Susana , Yuan Wei , Mackay Alan , Ferreira Ana , Pereira Rita , Bertan Claudia , Figueiredo Ines , Riisnaes Ruth , Rodrigues Daniel Nava , Sharp Adam , Goodall Jane , Boysen Gunther , Carreira Suzanne , Bianchini Diletta , Rescigno Pasquale , Zafeiriou Zafeiris , Hunt Joanne , Moloney Deirdre , Hamilton Lucy , Neves Rui P. , Swennenhuis Joost , Andree Kiki , Stoecklein Nikolas H. , Terstappen Leon W.M.M. , de Bono Johann S.
Published: April 2023

Summary of the CTC and WBC counts from both peripheral blood and apheresis product for all 14 patients, with additional clinical characteristics including sites of disease at apheresis and time to disease progression following apheresis procedure (when available). [ND = Not determined; WBC = White Blood Cells; CTC = Circulating Tumor Cells; PB = Peripheral Blood; Tot.Vol = Total Volume; Inc. = Increase]
Table S1 from Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Authors: Lambros Maryou B. , Seed George , Sumanasuriya Semini , Gil Veronica , Crespo Mateus , Fontes Mariane , Chandler Rob , Mehra Niven , Fowler Gemma , Ebbs Berni , Flohr Penny , Miranda Susana , Yuan Wei , Mackay Alan , Ferreira Ana , Pereira Rita , Bertan Claudia , Figueiredo Ines , Riisnaes Ruth , Rodrigues Daniel Nava , Sharp Adam , Goodall Jane , Boysen Gunther , Carreira Suzanne , Bianchini Diletta , Rescigno Pasquale , Zafeiriou Zafeiris , Hunt Joanne , Moloney Deirdre , Hamilton Lucy , Neves Rui P. , Swennenhuis Joost , Andree Kiki , Stoecklein Nikolas H. , Terstappen Leon W.M.M. , de Bono Johann S.
Published: April 2023

Baseline characteristics of study patients (n=14). *All values given are at time of apheresis unless otherwise specified. â^§The Eastern Cooperative Oncology Group (ECOG) performance status score ranges from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability.
Supplemental legend from MELK Inhibition in Diffuse Intrinsic Pontine Glioma
Authors: Meel Michaël H. , de Gooijer Mark C. , Guillén Navarro Miriam , Waranecki Piotr , Breur Marjolein , Buil Levi C.M. , Wedekind Laurine E. , Twisk Jos W.R. , Koster Jan , Hashizume Rintaro , Raabe Eric H. , Montero Carcaboso Angel , Bugiani Marianna , van Tellingen Olaf , van Vuurden Dannis G. , Kaspers Gertjan J.L. , Hulleman Esther
Published: April 2023

Supplemental legend
Table S1 from Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy
Authors: Gallois Claire , Taieb Julien , Le Corre Delphine , Le Malicot Karine , Tabernero Josep , Mulot Claire , Seitz Jean-François , Aparicio Thomas , Folprecht Gunnar , Lepage Côme , Mini Enrico , Van Laethem Jean-Luc , Emile Jean-François , Laurent-Puig Pierre
Published: April 2023

Table S1 shows the primer sequences and conditions for Methylation Specific PCR from the study of Lee et al. (25)
Figure S2 from Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy
Authors: Gallois Claire , Taieb Julien , Le Corre Delphine , Le Malicot Karine , Tabernero Josep , Mulot Claire , Seitz Jean-François , Aparicio Thomas , Folprecht Gunnar , Lepage Côme , Mini Enrico , Van Laethem Jean-Luc , Emile Jean-François , Laurent-Puig Pierre
Published: April 2023

Figure S2 shows the distribution of variables: MMR status, BRAF mutation, distal or proximal location of the tumor, according to CIMP status
Table S7 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Table S7. ROC curves for GC-SVM classifier, clinical stage, clinicopathological characteristics, molecular markers as predictors of 5 years DFS in training and validation cohorts.
Table S6 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Table S6. ROC curves for GC-SVM, clinical stage, clinicopathological characteristics as predictors of death within 5 years in training and validation cohorts.
Table S4 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Table S4. Univariable analysis of the GC-SVM classifier, patient characteristics, immunomarker expression, and overall survival in the internal and external cohorts.
Supplementary Figures from PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/Lymphoma
Authors: Chung Elaine Y. , Mai Yun , Shah Urvi A. , Wei Yongqiang , Ishida Elise , Kataoka Keisuke , Ren Xiaoxin , Pradhan Kith , Bartholdy Boris , Wei Xiaolei , Zou Yiyu , Zhang Jinghang , Ogawa Seishi , Steidl Ulrich , Zang Xingxing , Verma Amit , Janakiram Murali , Ye B. Hilda
Published: April 2023

Supplementary Figures Figure S1. Related to Materials and Methods Immunophenotype and viral gene expression status of the three NA-ATLL cell lines Figure S2. Related to Figure 1. PAK2 amplification pattern in ATLL and expression of PAK isoforms in published ATLL datasets Figure S3. Related to Figure 2. Survival curves for primary ATLL samples and ATLL cell lines treated with PF or IPA3 Figure S4. Related to Figure 3A. Apoptosis analysis of ATLL cell lines treated with PF for 24 and 48 hours Figure S5. Related to Figure 3B. Cell cycle analysis of Japanese ATLL cell lines treated with PF for 24 and 40 hours Figure S6. Related to Figure 3B. Cell cycle analysis of North American ATLL cell lines treated with PF for 24 and 40 hours Figure S7. Related to Figure 3C. Changes in the expression of apoptosis and cell survival regulators 48 hours post PF treatment Figure S8. Related to Figure 4. Roles of CADM1, PAK1, and PAK2 in cell adhesion to the HK feeder Figure S9. Related to Figure 5. Apoptosis and cell cycle analysis of ATL55T(+) and ATL43Tb(-) cells following siRNA-mediated PAK1 or PAK2 knock-down Figure S10. Related to Figure 5. Changes in proliferation and survival regulators in ATL43Tb(-) cells following siRNA-mediated PAK1 or PAK2 knock-down Figure S11. Related to Figure 6. PF response in CDX and PDX-derived xenograft models
Supplementary Figures from Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Authors: Margolin Kim , Morishima Chihiro , Velcheti Vamsidhar , Miller Jeffrey S. , Lee Sylvia M. , Silk Ann W. , Holtan Shernan G. , Lacroix Andreanne M. , Fling Steven P. , Kaiser Judith C. , Egan Jack O. , Jones Monica , Rhode Peter R. , Rock Amy D. , Cheever Martin A. , Wong Hing C. , Ernstoff Marc S.
Published: April 2023

Supplemental Figure 1. Effect of ALT-803 treatment on white blood cell and lymphocyte counts in i.v. dose cohorts Supplemental Figure 2. Circulating NK cell expansion during ALT-803 treatment Supplemental Figure 3. Effect of subcutaneous ALT-803 on circulating T cell expression of HLA-DR
Figure S5 from Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit
Authors: Jiang Yuming , Xie Jingjing , Han Zhen , Liu Wei , Xi Sujuan , Huang Lei , Huang Weicai , Lin Tian , Zhao Liying , Hu Yanfeng , Yu Jiang , Zhang Qi , Li Tuanjie , Cai Shirong , Li Guoxin
Published: April 2023

Figure S5. Kaplan-Meier survival analysis of DFS for patients in the external validation cohort according to the GC-SVM classifier stratified by clinicopathological risk factors. P-values were calculated by log-rank test.
Supplemental Figure 2 from Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling
Authors: Griewank Klaus G. , Koelsche Christian , van de Nes Johannes A.P. , Schrimpf Daniel , Gessi Marco , Möller Inga , Sucker Antje , Scolyer Richard A. , Buckland Michael E. , Murali Rajmohan , Pietsch Torsten , von Deimling Andreas , Schadendorf Dirk
Published: April 2023

Supplemental Figure 2: Copy Number Profiles of GNA11 and BAP1 mutated tumors
Supplementary Data from Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors
Authors: Ji Changhua , Roy Marc D. , Golas Jonathan , Vitsky Allison , Ram Sripad , Kumpf Steven W. , Martin Matthew , Barletta Frank , Meier William A. , Hooper Andrea T. , Sapra Puja , Khan Nasir K. , Finkelstein Martin , Guffroy Magali , Buetow Bernard S.
Published: April 2023

Table S1. Mean ({plus minus}SD) Toxicokinetic Parameters for Ipilimumab and Novolumab in Cynomolgus Monkeys Table S2 - Differentially expressed genes in the heart of ipilimumab and nivolumab treated cynos (adjusted P-value {less than or equal to} 0.05) Table S3 - Top 50 enriched pathways identified by IPA when using the data set of 882 analysis ready differentially expressed genes (adjusted P-value {less than or equal to} 0.05). Ratio: number of DE genes in a pathway divided by the number of genes comprised in the same pathway. Table S4: Top 25 networks identified based upon differentially expressed genes (adjusted P-value {less than or equal to} 0.05) in ipilimumab and nivolumab treated cynos. Table S5: Regulator effects networks generated using genes that are differentially expressed (adjusted P-value {less than or equal to} 0.05) in ipilimumab and nivolumab treated cynos. Upstream regulator and diseae& function cutoffs were each log P-value {less than or equal to} 10 and a z-score {greater than or equal to} |3| Table S6 - Differential expression of myocarditis- associated genes in the heart of ipilimumab and nivolumab treated cynos
Tables S1-S12, Figure S1-S3 from Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study
Authors: Filipits Martin , Dafni Urania , Gnant Michael , Polydoropoulou Varvara , Hills Margaret , Kiermaier Astrid , de Azambuja Evandro , Larsimont Denis , Rojo Federico , Viale Giuseppe , Toi Masakazu , Harbeck Nadia , Prichard Kathleen I. , Gelber Richard D. , Dinh Phuong , Zardavas Dimitrios , Leyland-Jones Brian , Piccart-Gebhart Martine J. , Dowsett Mitch
Published: April 2023

Table S1: Summary of baseline characteristics for the current analysis cohort vs. the Remainder of HERA patients Table S2: Summary of Disease-free Survival by subgroup of patients Table S3: Summary of Overall Survival by subgroup of patients Table S4: Comparison of median follow-up time (based on reverse censoring for OS) Table S5: Predictive effect of p27 biomarker (Low/High) for DFS: Cox proportional hazards model without adjustment for other variables. Table S6: Predictive effect of p27 biomarker (Low/High) for DFS, adjusted for variables of clinical interest: Multivariate Cox proportional hazards model. Table S7: Predictive effect of p27 biomarker (Low/High) for DFS, adjusted for variables of clinical interest and the predictive effect of ER Local: Multivariate Cox proportional hazards model Table S8: Predictive effect of p27 biomarker (Low/High) for DFS, adjusted for variables of clinical interest and the predictive effect of ESR1: Multivariate Cox proportional hazards model Table S9: Predictive effect of cyclin D1 biomarker (continuous) for DFS: Multivariate Cox proportional hazards model without adjustment for other variables. Table S10: Predictive effect of cyclin D1 (continuous) biomarker for DFS, adjusted for variables of clinical interest: Multivariate Cox proportional hazards model. Table S11: Predictive effect of cyclin D1 biomarker (continuous) for DFS, adjusted for variables of clinical interest and the predictive effect of ER Local: Multivariate Cox proportional hazards model Table S12: Predictive effect of cyclin D1 biomarker (continuous) for DFS, adjusted for variables of clinical interest and the predictive effect of ESR1: Multivariate Cox proportional hazards model Figure S1. A: Histogram of TOPO2A biomarker Figure S1.B Histogram of Ki67 biomarker Figure S1.C: Histogram of Cyclin D1 biomarker Figure S1.D: Histogram of p27 biomarker Figure S2.A: Ki67 distribution by TOPO2A level Figure S2.B: Cyclin D1 distribution by TOPO2A level Figure S2.C: p27 distribution by TOPO2A level Figure S3.A: Ki67 distribution by Cyclin D1 level Figure S3.B: p27distribution by Cyclin D1 level
Table S1- S2 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Authors: Fan Kaiji , Ritter Cathrin , Nghiem Paul , Blom Astrid , Verhaegen Monique E. , Dlugosz Andrzej , Ødum Niels , Woetmann Anders , Tothill Richard W. , Hicks Rodney J. , Sand Michael , Schrama David , Schadendorf Dirk , Ugurel Selma , Becker Jürgen C.
Published: April 2023

Information of MCC (Table S1) and non MCC cell lines (Table S2) used in the experiments.
Figure S1-S6 from Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma
Authors: Fan Kaiji , Ritter Cathrin , Nghiem Paul , Blom Astrid , Verhaegen Monique E. , Dlugosz Andrzej , Ødum Niels , Woetmann Anders , Tothill Richard W. , Hicks Rodney J. , Sand Michael , Schrama David , Schadendorf Dirk , Ugurel Selma , Becker Jürgen C.
Published: April 2023

Fig. S1: miR-375 demonstrates by far the highest ratio of extracellular to cellular miRNA; Fig. S2: Circulating cell-free miR-375 in serum discriminates healthy donors from MCC patients with tumor burden; Fig. S3: cf miR-375 serum level percentiles of retrospective discovery and training cohorts were applied to discriminate tumor or NED in prospective validation patient cohorts; Fig. S4: Correlation of circulating cell-free miR-375 serum levels with disease stage and tumor burden of MCC patients for the individual cohorts; Fig. S5 : Tracking the course of disease in MCC patients using circulating cell-free miR-375; Fig. S6: Comparison of receiver operating characteristic (ROC) curves for anti-MCPyV oncogenic protein antibodies and circulating cell-free miR-375 in serum of MCC patients.
Supplementary Data from Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers
Authors: Hagemann Urs B. , Ellingsen Christine , Schuhmacher Joachim , Kristian Alexander , Mobergslien Anne , Cruciani Véronique , Wickstroem Katrine , Schatz Christoph A. , Kneip Christoph , Golfier Sven , Smeets Roger , Uran Steinar , Hennekes Hartwig , Karlsson Jenny , Bjerke Roger M. , Ryan Olav B. , Mumberg Dominik , Ziegelbauer Karl , Cuthbertson Alan S.
Published: April 2023

The file contains Supporting Figures.